Woman's Hospital Prof Dr Jose Aristodemo Pinotti-CAISM, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.
Eur J Obstet Gynecol Reprod Biol. 2011 Apr;155(2):204-8. doi: 10.1016/j.ejogrb.2010.12.002. Epub 2010 Dec 28.
To evaluate the outcome of CIN 2 diagnosed by colposcopy-directed biopsy in women followed without treatment for 12 months and to verify whether the regression and progression of this lesion are associated with the woman's age at diagnosis and age at first sexual intercourse.
Women diagnosed with CIN 2 by biopsy and with previous cervical smear showing LSIL were included in this cohort study and followed up for one year with cervical smear and colposcopy every three months. The rates of progression, persistence and regression of the CIN 2 were evaluated. The Kruskal-Wallis test was used to analyze the woman's age at diagnosis, age at first sexual intercourse and interval since the first sexual intercourse according to the CIN 2 outcome, assuming a significance level of 5%.
At the end of 12 months of follow-up the CIN 2 regression rate was 74% (31/42), progression rate to CIN 3 was 24% (10/42) and in one case CIN 2 persisted (2%). Among women who had regression, this event was detected in the first six months of follow-up in 26 of the 31 cases. There was no statistically significant association between the evolution of CIN 2 and the woman's age at diagnosis, age at first sexual intercourse and interval since first sexual intercourse. Women whose lesions were restricted to one quadrant were more likely to have CIN 2 regression at three-month follow-up compared with women with a lesion extending to one or more quadrants (OR: 6.50; 95% CI: 1.20-35.23).
The results of this study indicate that the majority of CIN 2 diagnosed by biopsy in women with previous Pap smear showing LSIL will regress in 12 months and therefore an expectant approach could be considered in these cases, not only for young women. Nevertheless these findings are not conclusive, and larger studies are required in order to certify when it is safe to adopt expectant management for CIN 2.
评估阴道镜指导下活检诊断为 CIN 2 的患者在未经治疗的情况下随访 12 个月的结局,并验证该病变的消退和进展是否与患者的诊断年龄和首次性行为年龄有关。
本队列研究纳入了经活检诊断为 CIN 2 且宫颈液基细胞学检查(TCT)显示为低度鳞状上皮内病变(LSIL)的患者,每 3 个月进行一次宫颈 TCT 和阴道镜检查,随访 1 年。评估 CIN 2 的进展、持续和消退率。采用 Kruskal-Wallis 检验分析 CIN 2 结局与患者诊断年龄、首次性行为年龄和首次性行为后间隔时间的关系,假设显著性水平为 5%。
在 12 个月的随访期末,CIN 2 的消退率为 74%(31/42),进展为 CIN 3 的比例为 24%(10/42),1 例 CIN 2 持续存在(2%)。在消退的患者中,31 例中有 26 例在随访的前 6 个月内出现消退。CIN 2 的进展与患者的诊断年龄、首次性行为年龄和首次性行为后间隔时间之间无统计学显著相关性。病变局限于一个象限的患者在 3 个月随访时更有可能出现 CIN 2 消退,而病变累及一个或多个象限的患者则更有可能出现 CIN 2 持续存在(比值比:6.50;95%置信区间:1.20-35.23)。
本研究结果表明,大多数经活检诊断为 CIN 2 的患者在 TCT 显示为 LSIL 的情况下,在 12 个月内会消退,因此在这些病例中可以考虑采取期待治疗,不仅是年轻患者。然而,这些发现并不具有结论性,需要进行更大规模的研究以确定何时可以安全地对 CIN 2 采取期待管理。